Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

NASDAQ:RVPHW

Reviva Pharmaceuticals Holdings, Inc.

Last Close

0.50

29/04 20:00

Market Cap

108.04M

Beta: -

Volume Today

7.58K

Avg: -

PE Ratio

−2.39

PFCF: −4.77

Filings Not Available

Please Sign In To Use The Chat